These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18802648)

  • 1. Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists.
    Chu CM; Hung MS; Hsieh MT; Kuo CW; Suja TD; Song JS; Chiu HH; Chao YS; Shia KS
    Org Biomol Chem; 2008 Sep; 6(18):3399-407. PubMed ID: 18802648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
    J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists.
    Tai CL; Hung MS; Pawar VD; Tseng SL; Song JS; Hsieh WP; Chiu HH; Wu HC; Hsieh MT; Kuo CW; Hsieh CC; Tsao JP; Chao YS; Shia KS
    Org Biomol Chem; 2008 Feb; 6(3):447-50. PubMed ID: 18219411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.
    Menozzi G; Fossa P; Cichero E; Spallarossa A; Ranise A; Mosti L
    Eur J Med Chem; 2008 Dec; 43(12):2627-38. PubMed ID: 18342403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation, and structural studies on N1 and C5 substituted cycloalkyl analogues of the pyrazole class of CB1 and CB2 ligands.
    Krishnamurthy M; Li W; Moore BM
    Bioorg Med Chem; 2004 Jan; 12(2):393-404. PubMed ID: 14723958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
    Lange JH; Kruse CG
    Chem Rec; 2008; 8(3):156-68. PubMed ID: 18563799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.
    Tseng SL; Hung MS; Chang CP; Song JS; Tai CL; Chiu HH; Hsieh WP; Lin Y; Chung WL; Kuo CW; Wu CH; Chu CM; Tung YS; Chao YS; Shia KS
    J Med Chem; 2008 Sep; 51(17):5397-412. PubMed ID: 18712856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
    Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
    J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
    Reggio PH
    Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs.
    Thomas BF; Zhang Y; Brackeen M; Page KM; Mascarella SW; Seltzman HH
    AAPS J; 2006 Oct; 8(4):E665-71. PubMed ID: 17233530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB
    Asproni B; Murineddu G; Corona P; Pinna GA
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
    Pinna G; Loriga G; Lazzari P; Ruiu S; Falzoi M; Frau S; Pau A; Murineddu G; Asproni B; Pinna GA
    Eur J Med Chem; 2014 Jul; 82():281-92. PubMed ID: 24922543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
    Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.
    Dow RL; Hadcock JR; Scott DO; Schneider SR; Paight ES; Iredale PA; Carpino PA; Griffith DA; Hammond M; Dasilva-Jardine P
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5351-4. PubMed ID: 19683918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.